Eckert F, Gaipl U S, Niedermann G, Hettich M, Schilbach K, Huber S M, Zips D
Department of Radiation Oncology, Universitaetsklinikum Tuebingen, Eberhard-Karls-University Tuebingen, Tuebingen, Germany.
Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Clin Transl Radiat Oncol. 2017 Feb 4;2:29-35. doi: 10.1016/j.ctro.2016.12.006. eCollection 2017 Feb.
The revival of cancer immunotherapy has taken place with the clinical success of immune checkpoint inhibition. However, the spectrum of immunotherapeutic approaches is much broader encompassing T cell engaging strategies, tumour-specific vaccination, antibodies or immunocytokines. This review focuses on the immunological effects of irradiation and the evidence available on combination strategies with immunotherapy. The available data suggest great potential of combined treatments, yet also poses questions about dose, fractionation, timing and most promising multimodal strategies.
随着免疫检查点抑制在临床上取得成功，癌症免疫疗法得以复兴。然而，免疫治疗方法的范围要广泛得多，包括T细胞结合策略、肿瘤特异性疫苗接种、抗体或免疫细胞因子。本综述重点关注放疗的免疫效应以及与免疫疗法联合策略的现有证据。现有数据表明联合治疗具有巨大潜力，但也提出了关于剂量、分割、时机和最有前景的多模式策略的问题。
